Boris Tchounga1, Didier K Ekouevi, Eric Balestre, François Dabis. 1. aUniversité de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population HealthbProgramme PACCI, site de recherche ANRS, Abidjan, Côte d'IvoirecDépartement de Santé Publique, Université de Lomé, Lomé-Togo.
Abstract
PURPOSE OF REVIEW: People living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infected patients, either on ART or not. RECENT FINDINGS: Very few reports were published on mortality in people living with HIV-2 during the last 5 years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male sex, CD4 cell count less than 500 cell/μl, high plasma viral load, hemoglobin rate less than 8 g/dl and body mass index less than 18 kg/m. SUMMARY: People living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infected patients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the 'what to start' question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.
PURPOSE OF REVIEW: People living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infectedpatients, either on ART or not. RECENT FINDINGS: Very few reports were published on mortality in people living with HIV-2 during the last 5 years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male sex, CD4 cell count less than 500 cell/μl, high plasma viral load, hemoglobin rate less than 8 g/dl and body mass index less than 18 kg/m. SUMMARY:People living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infectedpatients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the 'what to start' question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.
Authors: Sanne Jespersen; Bo Langhoff Hønge; Joakim Esbjörnsson; Candida Medina; David da Silva Té; Faustino Gomes Correira; Alex Lund Laursen; Lars Østergaard; Andreas Andersen; Peter Aaby; Christian Erikstrup; Christian Wejse Journal: Trop Med Int Health Date: 2015-12-21 Impact factor: 2.622
Authors: Maarten F Schim van der Loeff; Natasha Larke; Steve Kaye; Neil Berry; Koya Ariyoshi; Abraham Alabi; Carla van Tienen; Aleksandra Leligdowicz; Ramu Sarge-Njie; Zacharias da Silva; Assan Jaye; Dominique Ricard; Tim Vincent; Sarah Rowland Jones; Peter Aaby; Shabbar Jaffar; Hilton Whittle Journal: Retrovirology Date: 2010-05-19 Impact factor: 4.602
Authors: Ingrid Peterson; Oluwatoyin Togun; Thushan de Silva; Francis Oko; Sarah Rowland-Jones; Assan Jaye; Kevin Peterson Journal: AIDS Date: 2011-11-13 Impact factor: 4.177
Authors: Euridice Martinez-Steele; Akum Aveika Awasana; Tumani Corrah; Saihou Sabally; Marianne van der Sande; Assan Jaye; Toyin Togun; Ramu Sarge-Njie; Samuel J McConkey; Hilton Whittle; Maarten F Schim van der Loeff Journal: AIDS Date: 2007-01-30 Impact factor: 4.177
Authors: Samuel Nyamweya; Andrea Hegedus; Assan Jaye; Sarah Rowland-Jones; Katie L Flanagan; Derek C Macallan Journal: Rev Med Virol Date: 2013-02-26 Impact factor: 6.989
Authors: Chijioke N Umunnakwe; Alice Duchon; Olga A Nikolaitchik; Sheikh Abdul Rahman; Yang Liu; Jianbo Chen; Sheldon Tai; Vinay K Pathak; Wei-Shau Hu Journal: J Mol Biol Date: 2020-11-19 Impact factor: 6.151
Authors: Joakim Esbjörnsson; Patrik Medstrand; Angelica A Palm; Philippe Lemey; Marianne Jansson; Fredrik Månsson; Anders Kvist; Zsófia Szojka; Antonio Biague; Zacarias José da Silva; Sarah L Rowland-Jones; Hans Norrgren Journal: mBio Date: 2019-01-08 Impact factor: 7.867
Authors: Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse Journal: AIDS Res Ther Date: 2019-09-05 Impact factor: 2.250
Authors: Jonathan M O Rawson; Olga A Nikolaitchik; Saurabh Shakya; Brandon F Keele; Vinay K Pathak; Wei-Shau Hu Journal: Microbiol Spectr Date: 2022-06-23
Authors: S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge Journal: AIDS Res Ther Date: 2020-02-04 Impact factor: 2.250